A qualitative analysis highlights barriers to access for advanced therapy medicinal products (ATMPs) in Europe, emphasizing the need for improved pathways to ensure these therapies reach patients. Stakeholder insights reveal critical gaps in the current system affecting cell therapy distribution.
why promising atmps fail to reach patients a qualitative stakeholder informed analysis of cell therapy access in europe
Original title: “Why promising ATMPs fail to reach patients: a qualitative stakeholder-informed analysis of cell therapy access in Europe.”